8-K
filed February 23, 2023, 6:59 PM ET
CIK 0001113148
M&A
confidence high
sentiment neutral
materiality 0.95
INFINITY PHARMACEUTICALS, INC.: restructuring charge — Infinity Pharma to merge with MEI Pharma; Infinity stockholders to receive 1.0449 MEI shares per share
INFINITY PHARMACEUTICALS, INC.
- Merger consideration: each Infinity share converts into 1.0449 MEI shares; Infinity stockholders will own ~42% of combined company on fully diluted basis.
- Closing conditions include stockholder approvals, regulatory, and net cash conditions: MEI must have ≥$80M net cash if close by June 30, 2023; Infinity must have ≥$4M net cash.
- Termination fees: MEI pays Infinity $4M under certain circumstances; Infinity pays MEI $2.9M under certain circumstances.
- Post-merger leadership: David M. Urso as CEO, Robert Ilaria Jr. as CMO, Stéphane Peluso as CSO; board 8 members (4 MEI, 3 Infinity, 1 joint).
- Infinity reduces headcount by 4 positions (~13%) with ~$2M costs in Q1 2023; Lawrence Bloch terminated, Adelene Perkins appointed PFO.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.8
Adelene Perkins was terminated as other_named_officer at INFINITY PHARMACEUTICALS, INC..
- Action
- terminated
Exact text from the filing
Upon, and in connection with, the closing of the Merger, Ms. Perkins’s employment with Infinity will terminate without Cause and she will join the MEI Board of Directors.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
INFINITY PHARMACEUTICALS, INC.: Adopted an amendment to the Amended and Restated Bylaws to add a new Section 6 of Article IX designating the Court of Chancery of Delaware as the exclusive forum for certain legal actions (effective 2023-02-22).
- Change
- bylaw amendment
- Effective
- 2023-02-22
Exact text from the filing
On February 22, 2023, Infinity’s Board of Directors adopted an amendment to Infinity’s Amended and Restated Bylaws (the “Bylaw Amendment”) to add a new Section 6 of Article IX thereto.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
INFINITY PHARMACEUTICALS, INC. entered into Agreement and Plan of Merger with MEI Pharma, Inc. and Meadow Merger Sub, Inc. (effective 2023-02-22).
- Action
- entry
- Agreement
- merger
- Counterparty
- MEI Pharma, Inc. and Meadow Merger Sub, Inc.
- Effective
- 2023-02-22
Exact text from the filing
On February 22, 2023, Infinity Pharmaceuticals, Inc., a Delaware corporation (“Infinity” or the “Company”), MEI Pharma, Inc., a Delaware corporation (“MEI”), and Meadow Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of MEI (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement")
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
INFINITY PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $2 million (4 positions, representing approximately 13% of the Company’s workforce).
- Type
- restructuring
- Charge
- approximately $2 million
- Headcount
- 4 positions, representing approximately 13% of the Company’s workforce
Exact text from the filing
On February 22, 2023, the Board of Directors of the Company approved a strategic restructuring of the Company to preserve the Company’s resources upon the signing of the Merger Agreement. The Company will reduce its overall headcount by 4 positions, representing approximately 13% of the Company’s workforce, in the first quarter of 2023. The Company currently expects to incur approximately $2 million in the first quarter of 2023 in connection with this workforce reduction.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.